FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Slides:

Advertisements

Similar presentations

FDA/Industry Statistics Workshop Washington D.C. September 27-29, 2006

Advertisements

Why does PAT need Rapid Microbiology Methods? S.Lonardi, P.J.Newby, D.Ribeiro, B.Johnson PAT Subcommittee meeting October 23, 2002.

Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

1 ITRC Mission ITRC is A state-led coalition working together with industry and stakeholders to achieve regulatory acceptance of environmental technologies.

Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office.

Implementation of Quality-by-Design: ONDQA Initiatives Advisory Committee for Pharmaceutical Science October 5, 2006 Chi-wan Chen, Ph.D. Deputy Director.

Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

Final Report on Process Analytical Technology (PAT) and Manufacturing Science Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science,

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

Codex Guidelines for the Application of HACCP

Ensuring Physical Stability of Pharmaceuticals: Can/should we improve our ability to identify and prevent physical changes? Ajaz S. Hussain, Ph.D. Deputy.

Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.

QAD's Customer Engagement Dan Blake Consultancy Development Director, QAD QAD Explore 2012.

Risk-Based CMC Review Paradigm

Organizational Gaps in Reaching the “Desired State” Helen Winkle.

One Quality Place Edison, NJ Visit: The Interrelationship.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.

D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Overview and Objectives Ajaz S. Hussain,

ENHANCING LEADERSHIP EFFECTIVENESS.  Transferring knowledge to application by learning and applying problem-solving strategies to real world, unpredictable.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration April.

INDIANA UNIVERSITY February 2000 Paul Shackelford Partner.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !

 Siemens Nederland N.V FDA13April Presented by Troy Logan at the Advisory Committee for Pharmaceutical Science meeting on April 13, 2004.

Office of Pharmaceutical Sciences

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Opening Remarks Ajaz S. Hussain, Ph.D.

10/11/ ENGINEERING RESEARCH CENTER FOR S TRUCTURED O RGANIC P ARTICULATE S YSTEMS RUTGERS UNIVERSITY PURDUE UNIVERSITY NEW JERSEY INSTITUTE OF TECHNOLOGY.

1 Basis of the Proposed Tactical Plan for a QbD approach for Quality Control and Assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director,

PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.

Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

Blend Uniformity: Update Ajaz S. Hussain, Ph.D.. Background Issue: Assuring and documenting “adequacy of mixing” operations –PQRI’s Proposal Stratified.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

© G.K.Raju, Ph.D. Confidential FDA Manufacturing Subcommittee Meeting July 20, 2004 G.K. Raju, Ph.D. Executive Director, MIT/PHARMI Massachusetts Institute.

1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.

Process Understanding and PAT

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration November.

Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

1 PAT Subcommittee Closing Report 12 March 2003 Tom Layloff Acting Chair.

Process Analytical Technologies (PATs), Applications and Benefits Working Group.

ICH Quality Topics Update

CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.

PAT Progress Report: 13 April 2004 ACPS Meeting Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science CDER, FDA.

Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS.

Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.

FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

ACPS Manufacturing Subcommittee July Standards for Pharmaceutical Applications of PAT Don Marlowe FDA Standards Coordinator Office of the Commissioner.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

The Interrelationship between PAT and Six Sigma

Quality System.

Standards for Pharmaceutical Applications of PAT

The Interrelationship between PAT and Six Sigma

PhUSE Computational Science

ICH Q9: Quality Risk Management

ICH Q9: Quality Risk Management

Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.

Presentation transcript:

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA February 26, 2002, Gaithersburg, MD.

Why were we here? To find a better way to serve our customers –Improving our manufacturing and associated regulatory processes –“Gap analysis” Understand the (potential) role PAT can play –develop a “common” understanding (same page) –identify real and perceived “regulatory hurdles” –initiate the process of finding “win - win” solutions

"Unable to determine the structure of this byproduct by spectroscopic methods, Nathan resorts to chemical degradation."

Expectation & Challenge At the end of this meeting: –Topics to be covered in the guidance (outline) –Layout general principles for setting specifications, validation, chemometrics –Consensus on benefits, definitions, terminology Different perspectives, expertise, and affiliations - can we come on the “same page” by the end of this meeting?

Accomplishments? “Same page” Topics to be covered in the guidance Consensus on “benefits”

PAT? Systems for continuous analysis and control of manufacturing processes based on real-time measurements, or rapid measurements during processing, of quality and performance attributes of raw and in-process materials and processes to assure acceptable end product quality at the completion of the process. Tools and systems that utilize real-time measurements, or rapid measurements during processing, of evolving quality and performance attributes of in-process materials to provide information to ensure optimal processing to produce final product that consistently conforms to established quality and performance standards.

Options for Introducing PAT A. Currently marketed “robust” products. PAT to improve efficiency (minimal improvement in quality assurance) B. Currently marketed products that need improvement. Step wise PAT approach - first improve quality and then improve the efficiency C. New products. PAT utilized throughout development and scale-up. Lab based tests to ensure shelf-life and/or for establishing “public standards.”

Next Steps ACPS meeting May 7 and 8, 2002 PAT Subcommittee meeting (June 02) –More focused discussion –Examples? What can I do to prepare for the 2nd meeting?

Win-Win Solution FDA –Unambiguous regulatory process for PAT –General Guidance for Industry Regulatory position on PAT, expectations and regulatory process –Collaborate with industry and academia Industry –Willingness to improve and change –Technical know-how (good science) and applications –Collaborate with FDA and academia Academia –Knowledge (public domain) –Provide future experts and leaders